Therefore, US FDA-approved oral activators of NRF2, such as dimethyl fumarate (DMF) [20,21] and simvastatin [22,23], are attractive targets for drug repurposing in SCD. This evidence concerns the gene NFE2L2 and Schnyder corneal dystrophy.